SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
2017: Jan Feb Mar Apr May Jun Jul Aug Sep
2017 - 2016 - 2015 - 2014

September 2017 Scleroderma News

Risk factors and outcome of Thai patients with scleroderma (SSc) renal crisis (SRC): a disease duration-matched case control study. SRC was an uncommon complication in Thai patients with SSc, but is associated with high mortality. PubMed, Int J Rheum Dis, 07/27/2017. (Also see Kidney (Renal) Involvement)

Downregulation of Aquaporin3 in Systemic Sclerosis (SSc) Dermal Fibroblasts. SSc manifestations like skin dryness, abnormal wound healing, and fibrotic lesions may be related to downregulation of AQP3 in SSc fibroblasts. PubMed, Iran J Allergy Asthma Immunol, 2017 Jun;16(3):228-234. (Also see Fibroblasts)

Severity and features of frailty in systemic sclerosis–associated interstitial lung disease (Ssc-ILD). This study showed that frailty is highly prevalent in SSc–ILD patients and may help identify those less likely to tolerate potentially toxic pharmaceutical therapies or lung transplant. PubMed, Respir Med, 2017 Aug;129:1-7. (Also see Symptoms and Complications of Pulmonary Fibrosis)

Preclinical Study Shows IVA337’s Potential in Treating SSc Skin and Cardiovascular Complications. Inventiva’s lead therapy candidate IVA337 for the treatment of systemic sclerosis (SSc) was shown to prevent the progression of lung fibrosis and the remodeling of blood vessels in preclinical animal models of lung fibrosis and systemic sclerosis. Scleroderma News, 07/28/2017. (Also see Clinical Trials)

Changes in pulmonary exercise haemodynamics in scleroderma (SSc): a 4–year prospective study. Patients with SSc developed mild deterioration of pulmonary exercise hemodynamics and exercise capacity over a 4–year follow–up period, indicating mild but significant progression of pulmonary vascular disease. PubMed, Eur Respir J, 2017 Jul 13;50(1). (Also see Pulmonary Hypertension)

Mechanics and prognostic value of left (LV) and right ventricular (RV) dysfunction in patients with systemic sclerosis. RV dysfunction was associated with adverse outcome, independent of and incremental to clinical and LV deformation parameters in SSc. European Heart Journal, 08/11/2017. (Also see Cardiac (Heart) Involvement)

The roles of dermal white adipose tissue (DWAT) loss in scleroderma skin fibrosis. The loss of skin–protective mechanisms with DWAT loss further contributes to skin fibrosis and injury. PubMed, Curr Opin Rheumatol, 08/10/2017. (Also see Skin Fibrosis)

Disease–related autoantibody (autoABs) profile in patients with systemic sclerosis (SSc). Anti-Topo I, anti-CENP, and anti-RNA pol III are the most prevalent autoAbs in SSc. PubMed, Autoimmunity, 2017 Jul 27:1-8. (Also see Antibodies)

Intestinal microbiome in scleroderma (SSC): recent progress. Therapeutic trials are needed to investigate whether dietary interventions or fecal transplantation can restore the gut microbial balance and improve health outcomes in SSc. PubMed, Curr Opin Rheumatol, 07/15/2017. (Also see Bowel Dysfunction)

Are there risk factors for scleroderma-related calcinosis? Calcinosis was common in both limited and diffuse systemic sclerosis; both longer disease duration and osteoporosis were independently associated with calcinosis. PubMed, Mod Rheumatol, 2017 Jul 19:1-5. (Also see Calcinosis)

Go to Scleroderma Medical News: August 2017
 
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including memorials for
Jim Miller, Arlene Marie Petulla, Frances Maude Baldwin Watson and Rubye Mai Blocker Westmoreland.
Thanks to Winn Schillberg for donating to scleroderma research.
Donate or Shop Now
 

TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!

Donate Now
Copyright 1998-2017, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.